OBJECTIVES: Human papillomavirus (HPV) infection is closely associated with the development of more than 95% of cervical cancer. Clinical trials using several chemopreventive agents are underway, but results are inconclusive. Most agents used in trials inhibited the growth of cancer cells in vitro, and about half of patients had some degree of clinical responses; however, the therapeutic effect was confounded by high rates of spontaneous regression and relapse. The selection of nontoxic agents especially food, beverage, and natural products that suppress oncogenic HPV, inhibit malignant transformation, and can additionally be used long term may be important for cervical cancer prevention. METHODS: We evaluated green tea compound (epigallocatechin gallate and polyphenols E) effects on immortalized cervical epithelial and cervical cancer cells. HPV-immortalized cervical epithelial cells, TCL1, and HPV-positive cervical cancer cells, Me180 and HeLa, were used in the study. The effects of green tea compounds on cell growth, apoptosis, cell cycle, and gene expression were examined and characterized. RESULTS: Both epigallocatechin gallate and polyphenols E inhibited immortalized cervical epithelial and cancer cell growth. Apoptosis induction and cell cycle changes were observed in a dose-dependent manner. Western blot analysis of apoptosis-related proteins, p53 and p21, showed dose-dependent increase, whereas p27 was not affected. HPV-E7 protein expression was decreased by green tea compounds. CONCLUSIONS: This study provides information on the potential mechanisms of action of green tea compounds in suppression of HPV-related cervical cells, and it will enable us to assess the feasibility of using these agents.
OBJECTIVES:Humanpapillomavirus (HPV) infection is closely associated with the development of more than 95% of cervical cancer. Clinical trials using several chemopreventive agents are underway, but results are inconclusive. Most agents used in trials inhibited the growth of cancer cells in vitro, and about half of patients had some degree of clinical responses; however, the therapeutic effect was confounded by high rates of spontaneous regression and relapse. The selection of nontoxic agents especially food, beverage, and natural products that suppress oncogenic HPV, inhibit malignant transformation, and can additionally be used long term may be important for cervical cancer prevention. METHODS: We evaluated green tea compound (epigallocatechin gallate and polyphenols E) effects on immortalized cervical epithelial and cervical cancer cells. HPV-immortalized cervical epithelial cells, TCL1, and HPV-positive cervical cancer cells, Me180 and HeLa, were used in the study. The effects of green tea compounds on cell growth, apoptosis, cell cycle, and gene expression were examined and characterized. RESULTS: Both epigallocatechin gallate and polyphenols E inhibited immortalized cervical epithelial and cancer cell growth. Apoptosis induction and cell cycle changes were observed in a dose-dependent manner. Western blot analysis of apoptosis-related proteins, p53 and p21, showed dose-dependent increase, whereas p27 was not affected. HPV-E7 protein expression was decreased by green tea compounds. CONCLUSIONS: This study provides information on the potential mechanisms of action of green tea compounds in suppression of HPV-related cervical cells, and it will enable us to assess the feasibility of using these agents.
Authors: M L Schoelch; J A Regezi; N P Dekker; I O Ng; A McMillan; B L Ziober; Q T Le; S Silverman; K K Fu Journal: Oral Oncol Date: 1999-05 Impact factor: 5.337
Authors: Ronald D Alvarez; Michael G Conner; Heidi Weiss; Patricia M Klug; Santosh Niwas; Upender Manne; James Bacus; Valeriy Kagan; Katherine C Sexton; Clinton J Grubbs; Isam-Eldin Eltoum; William E Grizzle Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-02 Impact factor: 4.254
Authors: Tetsuya Yamamoto; Stephen Hsu; Jill Lewis; John Wataha; Douglas Dickinson; Baldev Singh; Wendy B Bollag; Petra Lockwood; Eisaku Ueta; Tokio Osaki; George Schuster Journal: J Pharmacol Exp Ther Date: 2003-09-03 Impact factor: 4.030
Authors: Zhaoxia Zhang; Thomas J Knobloch; Leigh G Seamon; Gary D Stoner; David E Cohn; Electra D Paskett; Jeffrey M Fowler; Christopher M Weghorst Journal: Gynecol Oncol Date: 2011-08-09 Impact factor: 5.482
Authors: Francisco A R Garcia; Terri Cornelison; Tomas Nuño; David L Greenspan; John W Byron; Chiu-Hsieh Hsu; David S Alberts; H-H Sherry Chow Journal: Gynecol Oncol Date: 2014-01-02 Impact factor: 5.482
Authors: Paul Yaswen; Karen L MacKenzie; W Nicol Keith; Patricia Hentosh; Francis Rodier; Jiyue Zhu; Gary L Firestone; Ander Matheu; Amancio Carnero; Alan Bilsland; Tabetha Sundin; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang Journal: Semin Cancer Biol Date: 2015-04-11 Impact factor: 15.707
Authors: Kamran Harati; Björn Behr; Christoph Wallner; Adrien Daigeler; Tobias Hirsch; Frank Jacobsen; Marcus Renner; Ali Harati; Marcus Lehnhardt; Mustafa Becerikli Journal: Mol Med Rep Date: 2016-11-28 Impact factor: 2.952